Health canada authorizes moderna's omicron-targeting bivalent covid-19 vaccine in children & adolescents (6-17 years)

The recommendation is based on clinical data for moderna's bivalent omicron-targeting covid-19 vaccine, mrna.1273.214 moderna's bivalent omicron-targeting covid-19 vaccines (mrna.1273.214 (ba.1) & mrna.1273.222 (ba.4/5)) are currently authorized for use in individuals 18 years of age and older in canada both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mrna-1273, the company's prototype vaccine, against omicron (ba.4/5) in phase 2/3 clinical trials cambridge, ma / accesswire / february 17, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that health canada has authorized the use of its omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.214 (spikevax bivalent original/omicron) in children and adolescents 6 to 17 years of age. the authorizations are based on a 25 Μg booster dose for children ages 6 to 11 years old and a 50 Μg booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized covid-19 vaccines or a previous booster.
MRNA Ratings Summary
MRNA Quant Ranking